ASX healthcare share rockets 9% on upgraded profit growth guidance

This healthcare player has confirmed high growth for FY25.

ASX healthcare share Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) has rocketed out of the blocks on Friday after the company provided an update on its FY25 profit guidance.

Shares are racing 9% higher from the open and are fetching $32.00 apiece as investors react positively to the news.

Fisher & Paykel has been on a tear this year with the stock up 46.6% in that time, so today's price action continues this uptrend.

Let's see what the company posted.

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.

Image source: Getty Images

ASX healthcare updates H1 guidance

After updating the market on its business performance so far in FY25, the ASX healthcare share revised its projections higher.

Revenue is now projected to fall between $940 million and $950 million for the first half of FY25, marking an 18% increase compared to H1 last year.

Fisher & Paykel management also expects net profits to jump by 44% in the first half to $160 million, which is at the upper end of estimates.

This comes after it grew sales by 10% in FY24, leading to a 6% growth in net profit for the year. As such, the company expects big growth this financial year.

Management said the growth was driven by several factors, including successful new product launches and a higher-than-expected hospital census in both the Northern and Southern Hemispheres.

The company has also made notable strides in improving its gross margins. CEO Lewis Gradon highlighted this progress:

The year to date has begun strongly across all products and regions. In the Hospital product group, contributions include ongoing change in clinical practice, and a good response to new product introductions.

In addition, early indications are that the year to date includes a relatively high hospital census during the period in both the Northern and Southern Hemispheres as Northern Hemisphere seasonal hospitalisations persisted into the beginning of this current financial year and hospitals have returned to more normalised staffing and capacity.

This has seen investors gobbling up the ASX healthcare share en masse today, likely positioning for this expected growth.

Positive updates for the full year, too

Fisher & Paykel has also revised its full-year guidance. The ASX healthcare share didn't change its revenue expectations – it still expects sales of $1.9 billion to $2.0 billion.

However, it raised its profit forecasts by around $10 million, now estimating the bottom line at between $320 million and $370 million.

The company expects to maintain its current business momentum, supported by continued changes in clinical practice and the success of new products. CEO Gradon expressed optimism about the year ahead:

We expect the remainder of the financial year for our Hospital product group to have similar underlying contributions from changes to clinical practice and new product introductions.

We have not changed our view on the revenue guidance range for the full year due to the additional and variable impact of Northern Hemisphere seasonal hospitalisation rates, which historically occur towards the end of our second half.

Gradon described Fisher & Paykel's hospital products as "market leaders", and said that its sleep apnea masks were getting positive reviews.

Wilson's rated the stock a buy earlier this month, while Equity Trustees has placed the ASX healthcare stock on its 'shopping list' of top-quality businesses to consider for the long term.

ASX healthcare share snapshot

Fisher & Paykel's share price has been on a tear this year. The ASX healthcare share has just updated its outlook for both the first half and full year for FY25.

Shares in the company have climbed 54% in the last 12 months and are up 46.6% year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »